logo
Berry Fertility Launches Revamped App Amid 39% Jump in Egg Freezing Year-on-Year

Berry Fertility Launches Revamped App Amid 39% Jump in Egg Freezing Year-on-Year

Business Wire2 days ago

SAN FRANCISCO--(BUSINESS WIRE)-- Berry Fertility, a leading patient fertility management platform, today announced a revamped app with a powerful suite of new features designed to simplify and support every stage of the fertility journey, from IUI and IVF, to egg freezing and embryo transfers.
Fertility care is in high demand and short supply. Egg freezing cycles have more than doubled in the past five years, and each new year shows record-breaking growth. The Society for Assisted Reproductive Technology's most recent official data shows a surge in egg freezing cycles of 39.2%, the biggest single-year numerical jump on record.* Yet Assisted Reproductive Technology (ART) services like IVF still meet less than 30% of patient needs. Berry Fertility is helping bridge this access gap with a platform that puts personalized, tech-enabled fertility support in every patient's pocket.
With this new rollout, Berry customers can:
Access Step-by-Step Treatment Guides: Understand what to expect from IUI, IVF, egg freezing, embryo transfers, and timed intercourse with simplified breakdowns of complex care plans.
Manage Medications: Organize medications and dosing instructions more easily and confidently, with access to clear medical information and how-tos. To date, Berry has delivered over 200,000 medication reminders.
Smartly Add Medications: Use the phone's camera to quickly scan dozens of medications to import into the app.
Track Appointments, Symptoms, Lab Results, Milestones, and Reminders: Stay on top of everything — from ultrasound dates to medication times — with a custom fertility calendar. Track symptoms and store lab results to support more informed conversations with providers.
Access a Library of In-Depth Resources: Get a heads-up on what to expect and receive helpful resources at every stage of treatment, including articles, protocol diagrams, videos, common FAQ, and a fertility glossary.
Share With Your Support Network: Share a fertility treatment with anyone — a partner, parent, or friend — so they can follow along or provide support.
Talk to an Expert Anytime: Chat with the Berry team anytime for help with treatment questions, tech issues, or emotional support.
'Our team at Berry is made up of patients who have gone through fertility treatments themselves,' said Irene Alvarado, co-founder and CEO of Berry Fertility. 'We built Berry to be the tool we all wished we had — something that makes fertility care more accessible, less stressful, and a whole lot more human.'
Berry is available in all 50 U.S. states, Mexico, Australia, and Canada, and currently holds a five-star rating in the App Store, far above the industry standard of 2.4 stars. The app offers both a free tier and a premium version for $9.99/month or $72/year. To learn more, visit www.berryfertility.com. To make a request for feature improvements, partner, or get in touch, reach out to hello@berryfertility.com.
About Berry Fertility
Berry Fertility is a comprehensive patient management platform for IVF, IUI, embryo transfer, and egg freezing. Started in 2022 by a team of Google alumni, Berry Fertility streamlines fertility treatments for both patients and clinics. Through the platform, patients benefit from a seamless onboarding process, digital scheduling, and access to vital educational resources. Providers, meanwhile, can automate administrative tasks so they can get back to patient care. For more information visit, berryfertility.com.
*Official SART data published in the latest official report

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

timea day ago

  • Yahoo

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo

timea day ago

  • Yahoo

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, June 06, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 39,345 shares of the Company's common stock to four new employees (the "Inducement Grants") on June 5, 2025 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2025 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with Neurogene in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants have an exercise price per share that is equal to the closing price of Neurogene's common stock on the Grant Date. The Inducement Grants will vest over four years, with 25 percent vesting on the first anniversary of the vesting commencement date and thereafter in equal portions upon the lapse of each three-month period over the following 36-month period, subject to the employee's continued employment with Neurogene through the applicable vesting dates. About Neurogene The mission of Neurogene is to treat devastating neurological diseases to improve the lives of patients and families impacted by these rare diseases. Neurogene is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. This includes selecting a delivery approach to maximize distribution to target tissues and designing products to maximize potency and purity for an optimized efficacy and safety profile. The Company's novel and proprietary EXACT™ transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. Neurogene has constructed a state-of-the-art gene therapy manufacturing facility in Houston, Texas. CGMP production of NGN-401 was conducted in this facility and will support pivotal clinical development activities. For more information, visit View source version on Contacts Company Contact: Cara MayfieldVice President, Corporate Investor Contact: Melissa ForstArgot PartnersNeurogene@

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology

Yahoo

timea day ago

  • Yahoo

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology

IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine. With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty. This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. BANGKOK, June 06, 2025--(BUSINESS WIRE)--IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. As part of the congress, IBSA Derma will host a scientific symposium titled "The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line" scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead the session, focusing on the evolving approaches in regenerative aesthetic medicine, with particular attention to the clinical impact of hybrid cooperative complexes (HCCs) of hyaluronic acid and their role in tissue regeneration across different anatomical layers affected by aging. HCCs represent a new frontier in hyaluronic acid-based product formulation, made possible through NAHYCO® Technology, IBSA's patented thermal process that celebrates its 10th anniversary this year. This technological breakthrough is the foundation of the Profhilo® line and continues to be a milestone of IBSA Derma's innovation pathway. The Company's presence at IMCAS Asia is part of a broader strategic plan for expansion across the APAC region, an increasingly dynamic and high-potential market. In this context, IBSA Derma strengthened its regional presence last year with the opening of its regional hub in Singapore and the launch of a dedicated platform for Asian Key Opinion Leaders to share their clinical insights and expertise. "The strong growth we are experiencing in the APAC region stems from our solid collaboration with local distributors, which enable us to better understand the specific dynamics and cultural nuances of each market" – says Loy Derris, Business Development Director Dermoaesthetic Division North Asia. "Over the past 18 months, we have achieved remarkable results in countries such as Indonesia, Vietnam, Japan, and India, and we have recently entered the Thai market with great momentum. Looking ahead we are also looking enthusiastically toward promising new markets like Taiwan" – declares Magallon Riza Marie, Senior Strategic Marketing and Operational Lead Dermoaesthetic APAC Region. "Being at IMCAS Asia for the second year in a row is a valuable opportunity to strengthen our dialogue with physicians in the APAC Region and promote our concept of authentic beauty that embraces a holistic and overall wellness-oriented approach" – states Elisa Brozzelli, Brand Activation Manager Dermoaesthetic Division. IBSA Derma will also be present at Booth 8 - Level 2, where visitors can learn more about the latest solutions and innovations in aesthetic medicine. About IBSA IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA will celebrate the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA's growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people. About IBSA Derma IBSA has used its experience and expertise in the pharmaceutical field to branch out and develop medical devices for aesthetic medicine based on hyaluronic acid, thus creating a dedicated division: IBSA Derma. Through scientific expertise, continuous research, technological development and a modern production process, IBSA has become one of the leading pharmaceutical companies to produce hyaluronic acid for aesthetic medicine applications. IBSA Derma distinguishes itself in this vast market because it controls the entire product lifecycle, from the biofermentation production of the raw material to the ready-to-use final product in prefilled syringes. View source version on Contacts For further information: Giulia Drei, PR and Communication SpecialistDermoaesthetic Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store